AML carrying FLT3-ITD mutation has been recognized as a high-risk feature that is unfavorable for conventional chemotherapy38, and patients with this subtype of AML should be considered for clinical trials where available. This evidence concerns the gene FLT3 and acute myeloid leukemia.